Integrated Development of Glycobiologics: From Discovery to Applications in the Design of Nanoparticular Drug Delivery Systems

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 125-160

  Vauthier, Christine ^a   Bertholon, Isabelle ^a   Denis, Labarre ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Carbohydrate based nanoparticles; Glycobiologic integrated development; Nanoparticle drug carriers and new funtionalities

Indexed keywords

EID: 84884280387     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch1d     Document Type: Chapter

References (248)

1. Yoshida T (2001). Synthesis of polysaccharides having specific biological activities. Progress in Polymer Sci. 26:379-441.
2. Venkataraman G, Shriver Z, Raman R, et al. (1999). Sequencing complex polysaccharides. Science. 286:537-542.
3. Toukach F V, Shashkov A S (2001). Computer-assisted structural analysis of regular glycopolymers on the basis of 13C NMR data. Carbohydrate Research. 335:101-114.
4. Lee Y C (1996). Carbohydrate analyses with high-performance anion-exchange chromatography. J. Chromato. A. 720:137-149.
5. Gabius H-J (2004). The sugar code in drug delivery. Adv. Drug Del. Rev. 56:421-424.
6. Vauthier C, Couvreur P (2000). Development of Polysaccharide Nanoparticles as Novel Drug Carrier Systems. In D L Wise (ed.), Handbook of Pharmaceutical Controlled Release Technology. Marcel Dekker, New York, pp. 413-429.
7. Janes K A, Calvo P, Alonso M J (2001). Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Del. Rev. 47:83-97.
8. Prego C, Garcia M, Alonso M J (2005). Transmucosal macromolecular drug delivery. J. Control. Rel. 101:151-162.
9. Vauthier C, Fattal E, Labarre D (2004). From polymer chemistry and physicochemistry to nanoparticulate drug carrier design and applications. In Yaszemski M J, Trantolo D J, Lewandrowski K V, et al. (eds.), Tissue Engineering and Novel Delivery System: Marcel Dekker, New York, pp. 562-598.
10. Nori A, Kopecek J (2005). Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Del. Rev. 57:609-636.
11. Duncan R (2003). The dawning era of polymer therapeutics. Nature Reviews. Drug Disc. 2:347-360.
12. Nobs L, Buchegger F, Gurny R, et al. (2004). Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Phar. Sci. 93:1980-1992.
13. Torchilin V P (2005). Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Disc. 4:145-160.
14. Moghimi S M, Szebeni J (2003). Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress Lipid Res. 42:463-478.
15. Moghimi S M, Hunter A C, Murray J C (2001). Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53:283-318.
16. Gregoriadis G, McCormack B, Wang Z, Lifely R (1993). Polysialic acids: Potential in drug delivery. FEBS Lett. 315:271-276.
17. Olivier J-C, Vauthier C, Taverna M, et al. (1996). Stability of orosomucoid-coated polyisobutylcyanoacrylate nanoparticles in the presence of serum. J. Control. Rel. 40:157-168.
18. Passirani C, Ferrarini L, Barratt G, et al. (1999). Preparation and characterization of nanoparticles bearing heparin or dextran covalently-linked to poly(methyl methacrylate). J. Biomater. Sci. Polym. Ed. 10:47-62.
19. Chauvierre C, Labarre D, Couvreur P, et al. (2003). Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm. Res. 20:1786-1793.
20. Bertholon I, Vauthier C, Labarre D (2006). Core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: Influences of surface morphology, length and type of polysaccharide on complement activation in vitro. Pharm. Res. 23:1313-1323.
21. Bertholon I, Ponchel G, Labarre D (2006). Bioadhesive properties of poly(alkylcyanoacrylate) nanoparticles coated with polysaccharide. J. Nanosci. Nanotechnol. 6:3102-3109.
22. Sihorkar V, Vyas S P (2001). Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. J. Pharm. Pharmceut. Sci. 4:138-158.
23. Drotleff S, Lungwitz U, Breunig M, et al. (2004). Biomimetic polymers in pharmaceutical and biomedical sciences. Euro. J. Pharmaceutics and Biopharmaceutics. 58:385-407.
24. Bravo-Osuna I, Schmith T, Bernkop-Schnurch A (2006). Elaboration and characterization of thiolated chitosan-coated acrylic nanoparticles. Int. J. Pharm. 316:170-175.
25. Eylar E H (1966). On the biological role of glycoproteins. J. Theoret. Bio. 10:89-113.
26. Kimmerlin T, Seebach D (2005). "100 years of peptide synthesis": Ligation methods for peptide and protein synthesis with applications to beta-peptide assemblies. J. Peptide Res.: Official J. Amer. Peptide Soc. 65:229-260.
27. Zamecnik P (2005). From protein synthesis to genetic insertion. Ann. Rev. Biochem. 74:1-28.
28. Sharon N, Lis H (2004). History of lectins: From hemagglutinins to biological recognition molecules. Glycobiology. 14:53R-62R.
29. Khersonsky S M, Ho C M, Garcia M-A F, et al. (2003). Recent advances in glycomics and glycogenetics. Curr. Topics Medic. Chem. 3:617-643.
30. Petitou M, Casu B, Lindahl U (2003). 1976-1983, A critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie. 85:83-89.
31. Passirani C, Barratt G, Devissaguet J-P, et al. (1998). Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci. 62:775-785.
32. Labarre D, Vauthier C, Chauvierre C, et al. (2005). Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials. 26:5075-5084.
33. Di Marco A, Cassinelli G, Arcamone F (1981). The discovery of daunorubicin. Cancer Treat. Rep. 65:3-8.
34. Osborn H M, Evans P G, Gemmel N, et al. (2004). Carbohydrate-based therapeutics. J. Pharm. Pharmacol. 56:691-702.
35. Barchi J J (2000). Emerging roles of carbohydrates and glycomimetics in anticancer drug design. Curr. Pharm. Des. 6:485-501.
36. Kabel M A, Schols H A, Voragen A G J (2001). Mass determination of oligosaccharides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry following HPLC, assisted by on-line desalting and automated sample handling. Carboh. Polym. 44:161-165.
37. Broberg A, Thomsen K K, Duus J O (2000). Application of nano-probe NMR for structure determination of low nanomole amounts of arabinoxylan oligosaccharides fractionated by analytical HPAEC-PAD. Carboh. Res. 328:375-382.
38. Morelle W, Michalski J-C (2005). Glycomics and mass spectrometry. Curr. Pharm. Des. 11:2615-2645.
39. Iwafune M, Kakizaki I, Nakazawa H, et al. (2004). A glycomic approach to proteoglycan with a two-dimensional polysaccharide chain map. Analyt. Biochem. 325:35-40.
40. Ratner D M, Adams E W, Disney M D, et al. (2004). Tools for glycomics: Mapping interactions of carbohydrates in biological systems. Chembiochem: A Euro. J. Chem. Bio. 5:1375-1383.
41. Howbrook D N, van der Valk A M, O'Shaughnessy M C, et al. (2003). Developments in microarray technologies. Drug Dis. Today. 8:642-651.
42. Vives R R, Goodger S, Pye D A (2001). Combined strong anion-exchange HPLC and PAGE approach for the purification of heparan sulphate oligosaccharides. Biochem. J. 354:141-147.
43. Plante O J (2005). Combinatorial chemistry in glycobiology. Combinatorial Chem. & High Throughput Screening. 8:153-159.
44. Holemann A, Seeberger P H (2004). Carbohydrate diversity: Synthesis of glycoconjugates and complex carbohydrates. Curr. Opin. Biotech. 15:615-622.
45. Köhn M, Breinbauer R (2004). The Staudinger ligation-a gift to chemical biology. Angew. Chem. Int. Ed. Engl. 43:3106-3116.
46. de Kort M, Buijsman R C, van Boeckel C A A (2005). Synthetic heparin derivatives as new anticoagulant drugs. Drug Dis. Today. 10:769-779.
47. Croft S L, Coombs G H (2003). Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:502-508.
48. Adler-Moore J P, Proffitt R T (1993). Development, characterization, efficacy and mode of action of ambisome®. J. Liposome Res. 3:429-450.
49. Couvreur P, Barratt G, Fattal E, et al. (2002). Nanocapsule technology: A review. Crit. Rev. Ther. Drug Carrier Syst. 19:99-134.
50. Vauthier C, Dubernet C, Chauvierre C, et al. (2003). Drug delivery to resistant tumors: The potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Rel. 93:151-160.
51. Alonso M J (2004). Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 58:168-172.
52. Fouarge M, Dewulf M, Couvreur P, et al. (1989). Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasis. J. Microencapsulation. 6:29-34.
53. Gaspar R, Preat V, Opperdoes F R, et al. (1992). Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm. Res. 9:782-787.
54. Kattan J, Droz J P, Couvreur P, et al. (1992). Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Investigat. New Drugs. 10:191-199.
55. Barraud L, Merle P, Soma E, et al. (2005). Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 42:736-743.
56. Sangro B (2005). Refined tools for the treatment of hepatocellular carcinoma. J. Hepatol. 42:629-631.
57. Tyagi R, Lala S, Verma A K, et al. (2005). Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J. Drug. Target. 13:161-171.
58. Stolnik S, Dunn S E, Garnett M C, et al. (1994). Surface modification of poly(lactideco-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm. Res. 11:1800-1808.
59. Gref R, Minamitake Y, Peracchia M T, et al. (1994). Biodegradable long-circulating polymeric nanospheres. Science. 263:1600-1603.
60. Vauthier C, Couvreur P (2002). Biodegradation of poly(alkylcyanoacrylates) in Matsumara J P and Steinbuchel A (eds.), Handbook of Biopolymers, Wiley-VHC, Weinheim, Germany, pp. 457-490.
61. Ravi Kumar M N V, Bakowsky U, Lehr C M (2004). Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 25:1771-1777.
62. Bertholon-Rajot I, Labarre D, Vauthier C (2005). Influence of the initiator system, cerium-polysaccharide, on the surface properties of poly(isobutylcyanoacrylate) nanoparticles. Polymer. 46:1407-1415.
63. Schipper N G M, Olsson S, Hoogstraate J A, et al. (1997). Chitosans as Absorption Enhancers for Poorly Absorbable Drugs 2: Mechanism of Absorption Enhancement. Pharm. Res. 14:923-929.
64. Smith J M, Dornish M, Wood E J (2005). Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials. 26:3269-3276.
65. Lehr C-M, Bouwstra J A, Schacht E H, et al. (1992). In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78:43-48.
66. Schipper N G, Varum K M, Artursson P (1996). Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res. 13:1686-1692.
67. Chae S Y, Jang M-K, Nah J-W (2005). Influence of molecular weight on oral absorption of water soluble chitosans. J. Control. Rel. 102:383-394.
68. Thanou M, Verhoef J C, Junginger H E (2001). Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 52:117-126.
69. Avadi M R, Jalali A, Sadeghi A M M, et al. (2005). Diethyl methyl chitosan as an intestinal paracellular enhancer: ex vivo and in vivo studies. Int. J. Pharm. 293:83-89.
70. Sandri G, Rossi S, Ferrari F, et al. (2004). Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. Eur. J. Pharm. Sci. 21:351-359.
71. Kafedjiiski K, Föger F, Werle M, et al. (2005). Synthesis and in Vitro Evaluation of a Novel Chitosan-Glutathione Conjugate. Pharm. Res. 22:1480-1488.
72. Bernkop-Schnurch A, Pinter Y, Guggi D, et al. (2005). The use of thiolated polymers as carrier matrix in oral peptide delivery-Proof of concept. J. Control. Rel. 106:26-33.
73. De Campos A M, Sanchez A, Gref R, et al. (2003). The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur. J. Pharm. Sci. 20:73-81.
74. Yamamoto H, Takeuchi H, Hino T, et al. (2000). Mucoadhesive liposomes: Physicochemical properties and release behavior of water-soluble drugs from chitosan-coated liposomes. S.T.P. Pharma. Sci. 10:63-68.
75. Calvo P, Vila-Jato J L, Alonso M J (1997). Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int. J. Pharm. 153:41-50.
76. Yamamoto H, Kuno Y, Sugimoto S, et al. (2005). Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J. Control. Rel. 102:373-381.
77. Messai I, Delair T (2005). Adsorption of chitosan onto poly(D,L-lactic acid) particles: A physico-chemical investigation. Macromolecular Chem. Phys. 206:1665-1674.
78. Yang S C, Ge H X, Hu Y, et al. (2000). Formation of positively charged poly(butyl cyanoacrylate) nanoparticles stabilized with chitosan. Colloid Polym. Sci. 278:285-292.
79. Ponchel G, Irache J (1998). Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Del. Rev. 34:191-219.
80. Valenta C (2005). The use of mucoadhesive polymers in vaginal delivery. Adv. Drug Del. Rev. 57:1692-1712.
81. Song Y, Wang Y, Thakur R, et al. (2004). Mucosal drug delivery: Membranes, methodologies, and applications. Crit. Rev. Ther. Drug Carrier Syst. 21:195-256.
82. Barbault-Foucher S, Gref R, Russo P, et al. (2002). Design of poly-e-caprolactone nanosphere coated with bioadhesive hyaluronic acid for ocular delivery. J. Control. Rel. 83:365-375.
83. Leroux J-C, De Jaeghere F, Anner B, et al. (1995). An investigation on the role of plasma and serum opsonins on the evternalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. Life Sciences. 57:695-703.
84. Lenaerts V, Nagelkerke J F, Van Berkel T J, et al. (1984). In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells. J. Pharm. Sci. 73:980-982.
85. Lemarchand C, Gref R, Couvreur P (2004). Polysaccharide-decorated nanoparticles. Eur. J. Pharm. Biopharm. 58:327-341.
86. Torchilin V P (2000). Drug targeting. Eur. J. Pharm. Sci. 11:S81-S91.
87. Owens III D E, Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. In Press, Corrected Proof.
88. Torchilin V P, Trubetskoy V S (1995). Which polymers can make nanoparticulate drug carriers long-circulating? Adv. Drug Del. Rev. 16:141-155.
89. Passirani C, Barratt G, Devissaguet J P, et al. (1998). Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res. 15:1046-1050.
90. Lemarchand C, Gref R, Passirani C, et al. (2006). Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials. 27:108-118.
91. Jaulin N, Appel M, Passirani C, et al. (2000). Reduction of the uptake by a macrophagic cell line of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J. Drug Targeting. 8:165-172.
92. Rouzes C, Gref R, Leonard M, et al. (2000). Surface modification of poly(lactic acid) nanospheres using hydrophobically modified dextrans as stabilizers in an o/w emulsion/evaporation technique. J. Biomed. Mat. Res. 50:557-565.
93. Carreno M P, Maillet F, Labarre D, et al. (1988). Specific antibodies enhance Sephadexinduced activation to the alternative pathway in human serum. Biomaterials. 9:514-518.
94. Olivier J-C (1995). Développement d'un vecteur biomimétique, PhD Dissertation, Université Paris 11, Faculté de Pharmacie, Chatenay-Malabry. France, p. 133.
95. Maruyama A, Ishihara T, Kim J S, et al. (1997). Nanoparticle DNA carrier with poly (L-lysine) grafted polysaccharide copolymer and poly(D,L-lactic acid). Bioconjug. Chem. 8:735-742.
96. Benesch J, Tengvall P (2002). Blood protein adsorption onto chitosan. Biomaterials. 23:2561-2568.
97. Minami S, Suzuki H, Okamoto Y (1998). Chitin and chitosan activate complement via the alternative pathway. Carbohyd. Polym. 36:151-155.
98. Suzuki Y, Okamoto Y, Morimoto M, et al. (2000). Influence of physico-chemical properties of chitin and chitosan on complement activation. Carbohyd. Polym. 42:307-310.
99. Mitra S, Gaur U, Ghosh P C, et al. (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Rel. 74:317-323.
100. Banerjee T, Mitra S, Kumar Singh A, et al. (2002). Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int. J. Pharm. 243:93-105.
101. Banerjee T, Singh A K, Sharma R K, et al. (2005). Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: Interference by colloidal tin oxide particles. Int. J. Pharm. 289:189-195.
102. Son Y J, Jang J-S, Cho Y W, et al. (2003). Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J. Control Rel. 91:135-145.
103. Kato Y, Onishi H, Machida Y (2000). Evaluation of N-succinyl-chitosan as a systemic long-circulating polymer. Biomaterials. 21:1579-1585.
104. Hyung Park J, Kwon S, Lee M (2006). Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity. Biomaterials. 27:119-126.
105. Schauer R (1985). Sialic acids and their role as biological masks. Trends Biochem. Sci. 10:357-360.
106. Durocher J R, Payne R C, Conrad M E (1975). Role of sialic acid in erythrocyte survival. Blood. 45:11-20.
107. Schauer R (1992). Sialic acids regulate cellular and molecular recognition. In Ogura H, Hasegawa A, Suami T, Carbohydrates, Kodansha Ltd., Tokyo, pp. 340-354.
108. Jancik J, Schauer R (1974). Sialic acid-a determinant of the life-time of rabbit erythrocytes. Hoppe Seylers Z Physiol. Chem. 355:395-400.
109. Jancik J, Schauer R, Anders K H, et al. (1978). Sequestration of neuraminidasetreated erythrocytes. Cell Tiss. Res. 186:209-226.
110. Ourth D D, Bachinski L M (1987). Bacterial sialic acid modulates activation of the alternative complement pathway of channel catfish (Ictalurus punctatus). Devel. Compar. Immunol. 11:551-564.
111. Sakarya S, Oncu S (2003). Bacterial adhesins and the role of sialic acid in bacterial adhesion. Med. Sci. Monitor: Internat. Med. J. Exper. Clin. Res. 9:RA76-RA82.
112. Vimr E R, Kalivoda K A, Deszo E L, et al. (2004). Diversity of microbial sialic acid metabolism. Microbiol. Mol. Biol. Rev. 68:132-153.
113. Olivier J C, Taverna M, Vauthier C, et al. (1994). Capillary electrophoresis monitoring of the competitive adsorption of albumin onto the orosomucoid-coated polyisobutylcyanoacrylate nanoparticles. Electrophoresis. 15:234-239.
114. Huve P (1994). Comprendre et éviter la capture des nanoparticules de poly(acidelactique) par le système des phagocytes mononucléaires, PhD Dissertation, Université Paris Sud, Faculé de Pharmacie, Chatenay-Malabry, France, p. 193.
115. Yamauchi H, Yano T, Kato T, et al. (1995). Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes. Int. J. Pharm. 113:141-148.
116. Kazatchkine M D, Fearon D T, Silbert J E, et al. (1979). Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J. Exp. Med. 150:1202-1215.
117. Keuren J F, Wielders S J, Willems G M (2003). Thrombogenicity of polysaccharidecoated surfaces. Biomaterials. 24:1917-1924.
118. Weber N, Wendel H P, Ziemer G (2002). Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption. Biomaterials. 23:429-439.
119. Jeong S C, Yang B K, Ra K S (2004). Characteristics of anti-complementary biopolymer extracted from Coriolus versicolor. Carbohyd. Polym. 55:255-263.
120. Yamazaki N, Kojima S, Bovin N V, et al. (2000). Endogenous lectins as targets for drug delivery. Adv. Drug Del. Rev. 43:225-244.
121. Ehrhardt C, Kneuer C, Bakowsky U (2004). Selectins-an emerging target for drug delivery. Adv. Drug Del. Rev. 56:527-549.
122. Yamazaki N, Kojima S, Yokoyama H (2005). Biomedical nanotechnology for active drug delivery systems by applying sugar-chain molecular functions. Curr. Appl. Phys. 5:112-117.
123. Bies C, Lehr C-M, Woodley J F (2004). Lectin-mediated drug targeting: History and applications. Adv. Drug Del. Rev. 56:425-435.
124. Faivre V, Costa M d. L, Boullanger P, et al. (2003). Specific interaction of lectins with liposomes and monolayers bearing neoglycolipids. Chem. and Phys. of Lipids. 125:147-159.
125. Forssen E, Willis M (1998). Ligand-targeted liposomes. Adv. Drug Del. Rev. 29:249-271.
126. Minko T (2004). Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug Del. Rev. 56:491-509.
127. Lehr C-M, Gabor F (2004). Lectins and glycoconjugates in drug delivery and targeting. Adv. Drug Del. Rev. 56:419-420.
128. Montisci M J, Giovannuci G, Duchene D, et al. (2001). Covalent coupling of asparagus pea and tomato lectins to poly(lactide) microspheres. Int. J. Pharm. 215:153-161.
129. Reddy J A, Allagadda V M, Leamon C P (2005). Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr. Pharm. Biotechnol. 6:131-150.
130. Gao S, Chen J, Dong L, et al. (2005). Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. European J. of Pharmaceutics and Biopharmaceutics. 60:327-334.
131. Hubbard A L, Wilson G, Ashwell G, et al. (1979). An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver. Distribution of 125I-ligands among the liver cell types. J. Cell. Biol. 83:47-64.
132. Kishore U, Eggleton P, Reid K B (1997). Modular organization of carbohydrate recognition domains in animal lectins. Matrix Biol. 15:583-592.
133. Tanaka T, Fujishima Y, Hanano S, et al. (2004). Intracellular disposition of polysaccharides in rat liver parenchymal and nonparenchymal cells. Int. J. Pharm. 286:9-17.
134. Blondin C, Bataille L, Letourneur D (2000). Polysaccharides for vascular cell targeting. Crit. Rev. Ther. Drug Carrier Syst. 17:327-375.
135. Vercruysse K P, Prestwich G D (1998). Hyaluronate derivatives in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 15:513-555.
136. Sy M S, Guo Y J, Stamenkovic I (1991). Distinct effects of two CD44 isoforms on tumor growth in vivo. J. Exp. Med. 174:859-866.
137. Luo Y, Bernshaw N J, Lu Z-R, et al. (2002). Targeted Delivery of Doxorubicin by HPMA Copolymer-Hyaluronan Bioconjugates. Pharm. Res. 19:396-402.
138. Gunthert U, Hofmann M, Rudy W, et al. (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:13-24.
139. Entwistle J, Hall C L, Turley E A (1996). HA receptors: Regulators of signalling to the cytoskeleton. J. Cell Biochem. 61:569-577.
140. Danguy A, Camby I, Kiss R (2002). Galectins and cancer. Biochim. Biophys. Acta. 1572:285-293.
141. Julyan P J, Seymour L W, Ferry D R, et al. (1999). Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Control. Rel. 57:281-290.
142. Jensen K D, Kopeckova P, Bridge J H, et al. (2001). The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells. AAPS PharmSci. 3:E32.
143. Kim G-Y, Choi G-S, Lee S-H, et al. (2004). Acidic polysaccharide isolated from Phellinus linteus enhances through the up-regulation of nitric oxide and tumor necrosis factor-[alpha] from peritoneal macrophages. J. Ethnopharm. 95:69-76.
144. Zhang X Q, Wang X L, Zhang P C, et al. (2005). Galactosylated ternary DNA/polyphosphoramidate nanoparticles mediate high gene transfection efficiency in hepatocytes. J. Control Rel. 102:749-763.
145. Wu C, Wilson J, Wu G (1989). Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J. Biol. Chem. 264:16985-16987.
146. Wilson J, Grossman M, Wu C, et al. (1992). Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. J. Biol. Chem. 267:963-967.
147. Fajac I, Thévenot G, Bédouet L, et al. (2003). Uptake of plasmid/glycosylated polymer complexes and gene transfer efficiency in differentiated airway epithelial cells. J. Gene Med. 5:38-48.
148. Cade D, Ramus E, Rinaudo M, et al. (2004). Tailoring of bioresorbable polymers for elaboration of sugar-functionalized nanoparticles. Biomacromol. 5:922-927.
149. Racles C, Hamaide T (2005). Synthesis and Characterization of Water Soluble Saccharide Functionalized Polysiloxanes and Their Use as Polymer Surfactants for the Stabilization of Polycaprolactone Nanoparticles. Macromol. Chem. and Phys. 206:1757-1768.
150. Jeong Y-I, Seo S-J, Park I-K, et al. (2005). Cellular recognition of paclitaxelloaded polymeric nanoparticles composed of poly([gamma]-benzyl l-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm. 296:151-161.
151. Uchida T, Serizawa T, Ise H, et al. (2001). Graft copolymer having hydrophobic backbone and hydrophilic branches. 33. Interaction of hepatocytes and polystyrene nanospheres having lactose-immobilized hydrophilic polymers on their surfaces. Biomacromol. 2:1343-1346.
152. Sinha V R, Kumria R (2001). Polysaccharides in colon-specific drug delivery. Int. J. Pharm. 224:19-38.
153. Jozefowicz M, Jozefonvicz J (1997). Randomness and biospecificity: random copolymers are capable of biospecific molecular recognition in living systems. Biomaterials. 18:1633-1644.
154. Walker J B (2002). Enzymatic synthesis of aminoglycoside antibiotics: novel adenosylmethionine: 2-deoxystreptamine N-methyltransferase activities in hygromycin Band spectinomycin-producing Streptomyces spp. and uses of the methylated products. Appl. Environ. Microbiol. 68:2404-2410.
155. Macmillan D, Daines A M (2003). Recent developments in the synthesis and discovery of oligosaccharides and glycoconjugates for the treatment of disease. Curr. Med. Chem. 10:2733-2773.
156. Wong C H, Bryan M C, Nyffeler P T, et al. (2003). Synthesis of carbohydrate-based antibiotics. Pure Appl. Chem. 75:179-186.
157. Basu M K, Lala S (2004). Macrophage specific drug delivery in experimental leishmaniasis. Curr. Mol. Med. 4:681-689.
158. Donald P R, Sirgel F A, Venter A, et al. (2001). The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. J. Antimicrob. Chemother. 48:877-880.
159. Fielding R M, Lewis R O, Moon-McDermott L (1998). Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Pharm. Res. 15:1775-1781.
160. Fielding R M, Moon-McDermott L, Lewis R O, et al. (1999). Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. Antimicrob. Agents Chemother. 43:503-509.
161. Fattal E, Youssef M, Couvreur P, et al. (1989). Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob. Agents Chemother. 33:1540-1543.
162. Pinto-Alphandary H, Andremont A, Couvreur P (2000). Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents. 13:155-168.
163. Schiffelers R, Storm G, Bakker-Woudenberg I (2001). Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 48: 333-344.
164. Barratt G (2003). Colloidal drug carriers: achievements and perspectives. Cell. Mol. Life Sci. (CMLS). 60:21-37.
165. Fattal E, Balland O, Alphandary H, et al. (1993). Colloidal carriers of antibiotics as an alternative approach for the treatment of intracellular infections. In Raoult D (ed.), Antimicrobial agents and intracellular pathogens: CRC Press, Boca Raton, F.L., pp. 63-72.
166. Senel S, McClure S J (2004). Potential applications of chitosan in veterinary medicine. Adv. Drug Del. Rev. 56:1467-1480.
167. Rabea E I, Badawy M E-T, Stevens C V, et al. (2003). Chitosan as antimicrobial agent: applications and mode of action. Biomacromol. 4:1457-1465.
168. Zheng L Y, Zhu J F (2003). Study on antimicrobial activity of chitosan with different molecular weights. Carbohyd. Polym. 54:527-530.
169. Jeon Y J, Park P J, Kim S K (2001). Antimicrobial effect of chitooligosaccharides produced by bioreactor. Carbohyd. Polym. 44:71-76.
170. Liu H, Du Y, Wang X, et al. (2004). Chitosan kills bacteria through cell membrane damage. Intern. J. Food Microbiol. 95:147-155.
171. Avadi M R, Sadeghi A M M, Tahzibi A, et al. (2004). Diethylmethyl chitosan as an antimicrobial agent: Synthesis, characterization and antibacterial effects. Euro. Polym. J. 40:1355-1361.
172. Carlucci M J, Pujol C A, Ciancia M, et al. (1997). Antiherpetic and anticoagulant properties of carrageenans from the red seaweed Gigartina skottsbergii and their cyclized derivatives: correlation between structure and biological activity. Int. J. Biol. Macromol. 20:97-105.
173. Yoshida R L, Nakashima H, Premanathan M, et al. (2000). Specific biological activities of Chinese lacquer polysaccharides. Carbohyd. Polym. 43:47-54.
174. Hattori K, Yoshida T, Nakashima H, et al. (1998). Synthesis of sulfonated aminopolysaccharides having anti-VIH and blood anticoagulant activities. Carbohyd. Res. 312:1-8.
175. Seddiki N, Mbemba E, Letourneur D, et al. (1997). Antiviral activity of derivatized dextrans on HIV-1 infection of primary macrophages and blood lymphocytes. Biochim. Biophys. Acta. 1362:47-55.
176. Ghosh P, Adhikari U, Ghosal P K (2004). In vitro anti-herpetic activity of sulfated polysaccharide fractions from Caulerpa racemosa. Phytochem. 65:3151-3157.
177. Hobbs S K, Monsky W L, Yuan F, et al. (1998). Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA, 95:4607-4612.
178. Krishna R, Mayer L D (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11:265-283.
179. Jain K K (2005). Nanotechnology-based Drug Delivery for Cancer. Technol. Cancer Res. Treat. 4:407-416.
180. Jain R K (2001). Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Rel. 74:7-25.
181. Brigger I, Dubernet C, Couvreur P (2002). Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Rev. 54:631-651.
182. Minko T, Dharap S S, Pakunlu R I, et al. (2004). Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets. 5:389-406.
183. Couvreur P, Vauthier C. Nanotechnology in pharmacology. Submitted.
184. Qi L, Xu Z, Jiang X, et al. (2005). Cytotoxic activities of chitosan nanoparticles and copper-loaded nanoparticles. Bioorg. Medic. Chem. Lett. 15:1397-1399.
185. Berry D, Lynn D M, Sasisekharan R (2004). Poly(b-amino ester)s promote cellular uptake of heparin and cancer cell death. Chem. Bio. 11:487-498.
186. Linhardt R J (2004). Heparin-induced cancer cell death. Chem. Bio. 11:420-422.
187. Peng Y, Zhang L, Zeng F, et al. (2005). Structure and antitumor activities of the watersoluble polysaccharides from Ganoderma tsugae mycelium. Carbohyd. Polym. 59:385-392.
188. Zhang M, Zhang L, Cheung P C K, et al. (2004). Molecular weight and anti-tumor activity of the water-soluble polysaccharides isolated by hot water and ultrasonic treatment from the sclerotia and mycelia of Pleurotus tuber-regium. Carbohyd. Polym. 56:123-128.
189. Yoo S-H, Yoon E J, Cha J, et al. (2004). Antitumor activity of levan polysaccharides from selected microorganisms. Internat. J. Biol. Macromol. 34:37-41.
190. Ho J C K, Konerding M A, Gaumann A, et al. (2004). Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice. Life Sci. 75:1343-1356.
191. Cheng J-J, Huang N-K, Chang T-T, et al. (2005). Study for anti-angiogenic activities of polysaccharides isolated from Antrodia cinnamomea in endothelial cells. Life Sci. 76:3029-3042.
192. Peng Y, Zhang L, Zeng F, et al. (2003). Structure and antitumor activity of extracellular polysaccharides from mycellium. Carbohyd. Polym. 54:297-303.
193. Kabanov A V, Batrakova E V, Miller D W (2003). Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Del. Rev. 55:151-164.
194. Saima Y, Sarkar K K, Sen Sr A K, et al. (2000). An antitumor pectic polysaccharide from Feronia limonia. Int. J. Biol. Macromol. 27:333-335.
195. Clowes A W, Karnowsky M J (1977). Supression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 265:625-626.
196. Logeart D, Prigent-Richard S, Boisson-Vidal C, et al. (1997). Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell porliferation. II. Degradation and molecular weight effect. Euro. J. Cell Bio. 74:385-390.
197. Logeart D, Prigent-Richard S, Jozefonvicz J, et al. (1997). Fucans,
198. Mestries P, Borchiellini C, Barbaud C, et al. (1998). Chemicaly modified dextrans modulate expression of collagen phenotype by cultured smooth muscle cells in relation to the degree of carboxymethyl, benzylamide, and sulfation substitution. J. Biomed. Mater. Res. 42:286-294.
199. Chupa J M, Foster A M, Summer S R, et al. (2000). Vascular cell response to polysaccharide materials: in vitro and in vivo evaluations. Biomaterials. 21:2315-2322.
200. Sato N, Nakazawa F, Ito T (2003). The structure of the antigenic polysaccharide produced by Eubactrium saburreum T15. Carbohyd. Res. 338:923-930.
201. Fattom A I, Horwith G, Fuller S (2004). Development of StaphVAX(TM), a polysaccharide conjugate vaccine against S. aureus infection: From the lab bench to phase III clinical trials. Vaccine. 22:880-887.
202. Menzel M, Muellinger B, Weber N, et al. (2005). Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine. 23:5113-5119.
203. Ruben F L, Froeschle J E, Meschievitz C, et al. (2001). Choosing a route of administration for quadrivalent menigococcal polysaccharide vaccine: intramuscular versus subcutaneous. Clin. Infec. Dis. 32:170-172.
204. Moe G R, Tan S, Granoff D M (1999). Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol. Med. Microbiol. 26:209-226.
205. Westerfeld N, Zurbriggen R (2005). Peptides delivered by immunostimulating reconstituted influenza virosomes. J. Pept. Sci. 11:707-712.
206. Moser C, Metcalfe I C, Viret J F (2003). Virosomal adjuvanted antigen delivery systems. Expert Rev. Vacc. 2:189-196.
207. Garcea R L, Gissmann L (2004). Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr. Opin. Biotechnol. 15:513-517.
208. Morein B, Hu K F, Abusugra I (2004). Current status and potential application of ISCOMs in veterinary medicine. Adv. Drug Del. Rev. 56:1367-1382.
209. Kreuter J (1995). Nanoparticles as adjuvants for vaccines. Pharm. Biotechnol. 6:463-472.
210. Koping-Hoggard M, Sanchez A, Alonso M J (2005). Nanoparticles as carriers for nasal vaccine delivery. Expert Rev. Vacc. 4:185-196.
211. Chauvierre C, Couvreur P, Labarre D, et al. (2002). Copolymères à structure séquencée composé d'un segment saccharidique lié à au moins un segment hydrophobe bioérodable et particules correspondantes, Patent n°WO 02/399-79.
212. Salek-Ardakani S, Arrand J R, Shaw D, et al. (2000). Heparin and heparan sulfate bind interleukin-10 and modulate its activity. Blood. 96:1879-1888.
213. Bland E J, Keshavarz T, Bucke C (2004). The influence of small oligosaccharides on the immune system. Carbohyd. Res. 339:1673-1678.
214. da Silva B P, Parente J P (2003). Bioactive polysaccharides from Costus spicatus. Carbohyd. Polym. 51:239-242.
215. Gan L, Zhang S H, Liu Q, et al. (2003). A polysaccahride-protein complex from Lyciul barbarum upregukates cytokine expression in human peripheral blood mononuclear cells. Euro. J. Pharmac. 471:217-222.
216. Zhao G, Kan J, Li Z, et al. (2005). Structural features and immunological activity of a polysaccharide from Dioscorea opposita Thunb roots. Carbohyd. Polym. 61:125-131.
217. Peluso G, Petillo O, Ranieri M, et al. (1994). Chitosan-mediated stimulation of macrophage function. Biomaterials. 15:1215-1220.
218. Han Y, Zhao L, Yu Z, et al. (2005). Role of mannose receptor in oligochitosanmediated stimulation of macrophage function. Int. Immunopharmacol. 5:1533-1542.
219. Klokkevold P R, Fukayama H, Sung E C, et al. (1999). The effect of chitosan (poly-Nacetyl glucosamine) on lingual hemostasis in heparinized rabbits. J. Oral Maxillofac. Surg. 57:49-52.
220. Jordan R, Beeler D, Rosenberg R (1979). Fractionation of low molecular weight heparin species and their interaction with antithrombin. J. Biolog. Chem. 254:2902-2913.
221. Zeerleder S, Mauron T, Lämmle B, et al. (2002). Effect of low molecular weight dextran sulfate on coagulation and platelet function tests. Thrombosis Res. 105:441-446.
222. Mauzac M, Jozefonvicz J (1984). Anticoagulant activity of dextra derivatives. Part I: synthesis and characterization. Biomaterials. 5:301-304.
223. Magel-Din Hussein D, Helmy W A, Salem H M (1998). Biological activities of some galactomannans and their sulfated derivatives. Phytochem. 48:479-484.
224. Alban S, Schauerte A, Franz G (2002). Anticoagulant sulfated polysaccharides: Part I. Synthesis and structure-activity relationship of new pullulan sulfates. Carbohyd. Polym. 47:267-276.
225. Krentsel L, Chaubet F, Rebrov A, et al. (1997). Anticoagulant activity of functionalized dextrans. Structure analyses of carboxymethylated dextran and first Monte Carlo simulations. Carbohyd. Polym. 33:63-71.
226. Ronghua H, Yumin D, Jianhong Y (2003). Preparation and anticoagulant activity of carboxybutyrylated hydroxyethyl chitosan sulfates. Carbohyd. Polym. 51:431-438.
227. Siddhanta A K, Shanmugam M, Mody K H, et al. (1999). Sulphated polysaccharides of Codium dwarkense Boergs. from the west coast of India: Chemical composition and blood anticoagulant activity. Int. J. Biol. Macromol. 26:151-154.
228. Ross B P, Toth I (2005). Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr. Drug Deliv. 2:277-287.
229. Rajaonarivony M, Vauthier C, Couarraze G, et al. (1993). Development of a new drug carrier made from alginate. J. Pharm. Sci. 82:912-917.
230. Vila A, Sanchez A, Tobio M, et al. (2002). Design of biodegradable particles for protein delivery. J. Control Rel. 78:15-24.
231. Sakuma S, Hayashi M, Akashi M (2001). Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv. Drug Del. Rev. 47:21-37.
232. Alonso M J, Sanchez A (2003). The potential of chitosan in ocular drug delivery. J. Pharm. Pharmacol. 55:1451-1463.
233. Behrens I, Pena A I V, Alonso M J, et al. (2002). Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 19:1185-1193.
234. Mao S, Germershaus O, Fischer D, et al. (2005). Uptake and Transport of PEG-Graft-Trimethyl-Chitosan Copolymer-Insulin Nanocomplexes by Epithelial Cells. Pharmac. Res., In Press.
235. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, et al. (1999). Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles. Pharm. Res. 16:1576-1581.
236. Borges O, Borchard G, Verhoef J C, et al. (2005). Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int. J. Pharm. 299:155-166.
237. Douglas K L, Tabrizian M (2005). Effect of experimental parameters on the formation of alginate-chitosan nanoparticles and evaluation of their potential application as DNA carrier. J. Biomater. Sci. Polym. Ed. 16:43-56.
238. Li X W, Lee D K L, Chan A S C, Alpar H O (2003). Sustained expression in mammalian cells with DNA complexed with chitosan nanoparticles. Biochimica et Biophysica Acta (BBA)-Gene Struc. Expres. 1630:7-18.
239. Peng J, Xing X, Wang K, et al. (2005). Influence of anions on the formation and properties of chitosan-DNA nanoparticles. J. Nanosci. Nanotechnol. 5:713-717.
240. Mansouri S, Cuie Y, Winnik F, et al. (2006). Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials. 27:2060-2065.
241. Ravi Kumar M N V, Samedt M, Mohapatra S S, et al. (2004). Cationic silica nanoparticles as gene carriers: synthesis, characterization and transfection efficiency in vitro and in vivo. J. Nanosci. Nanotechnol. 4:876-881.
242. Messai I, Lamalle D, Munier S, et al. (2005). Poly(D,L-lactic acid) and chitosan complexes: interactions with plasmid DNA. Colloids and Surfaces A: Physicochem. Engin. Aspects. 255:65-72.
243. Zimmer A (1999). Antisense Oligonucleotide Delivery with Polyhexylcyanoacrylate Nanoparticles as Carriers. Methods. 18:286-295.
244. Zobel H P, Kreuter J, Werner D, et al. (1997). Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. Antisense & Nucleic Acid Drug Dev. 7:483-493.
245. Aynie I, Vauthier C, Chacun H, et al. (1999). Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 9:301-312.
246. El-Aneed A (2004). An overview of current delivery systems in cancer gene therapy. J. Control. Rel. 94:1-14.
247. Riggs A (1981). Preparation of blood hemoglobins of vertebrates. Methods Enzymol. 76:5-29.
248. Chauvierre C, Marden M C, Vauthier C (2004). Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. Biomaterials. 24:3081-3086.